TrialHuman vaccines & immunotherapeutics2024

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life.

Tessa Hosman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.